Federal contractor · CARLSBAD, CA

ARIMA GENOMICS, INC.

No contract obligations recorded for ARIMA GENOMICS, INC. in FY2026. Since FY2018: $457.2K.

Obligations · FY2026
$0
New awards
0
Sole-source
—
Single offer
—
UEI
PKRJJSZRJ6M3
Small business
Open in the contracts explorerRelationship graph

Spending by fiscal year

Obligations per federal fiscal year (October–September).

  1. 13.1KFY2018
  2. 43.5KFY2019
  3. 105.7KFY2020
  4. 41.8KFY2021
  5. 97KFY2022
  6. 61.8KFY2023
  7. 41.7KFY2024
  8. 52.5KFY2025

Top buying agencies

Obligations in FY2026.

No contract obligations recorded for ARIMA GENOMICS, INC. in FY2026.

What was bought · Where the work was performed

Obligations in FY2026.

What was bought

Where the work was performed

Integrity signals

Shares of the year's obligations, next to the country's.

Federal grants & assistance received

Grants, loans (counted at their subsidy cost), direct payments and insurance, by fiscal year of the action (USAspending.gov, FABS). Reported apart from contracts and never added to them.

ARIMA GENOMICS, INC. received $0 in federal assistance in FY2026, on 1 actions (0 new awards).

Assistance · FY2026
$0
New awards
0
Actions
1
Since FY2021
$11.2M

Assistance by fiscal year

  1. 3.2MFY2021
  2. 2MFY2022
  3. 3.1MFY2023
  4. 3MFY2024
  5. 0FY2025
  6. 0FY2026

Largest awards

  1. SCALABLE SINGLE-CELL WORKFLOW FOR MULTIOMIC ANALYSES OF CHROMATIN INTERACTIONS, ACCESSIBILITY, GENE EXPRESSION AND CELL SURFACE PROTEINS TO…$2.1M
    93.859 · Biomedical Research and Research Training· National Institutes of Health· Project grant· Feb 14, 2023 – Jun 16, 2026· R44GM149103

Source: Federal financial assistance transactions (Financial Assistance Broker Submission) (U.S. Department of the Treasury, USAspending.gov), data current to Oct 8, 2026, loaded Oct 8, 2026 · FY2021–FY2026.

Competitors

Companies that win from the same buyers in the same markets: obligations by agency and industry compared over the last three fiscal years.

Compared on 2 markets (agency × industry), FY2024–FY2026.

  1. MAKERERE UNIVERSITY CENTRE FOR HEALTH & POPULATION RESEARCH$82.7K
    KAMPALA, UGA · 88% of this company's obligations are in markets they both serveNational Institutes of Health · Scientific research and development services
  2. MURTY PHARMACEUTICALS, INC.$83.5K0% in FY2026
    LEXINGTON, KY · 88% of this company's obligations are in markets they both serveNational Institutes of Health · Scientific research and development services
  3. BIOSKRYB GENOMICS, INC.$77.8K−41% in FY2026
    DURHAM, NC · 83% of this company's obligations are in markets they both serveNational Institutes of Health · Scientific research and development services

Showing the top 3 of 25 competitors. Open the profile for the full list.

Who sells to the same buyers in the same markets, not who wins against whom on a given contract. Prime contract obligations by the agency and NAICS code of each award; subawards are never added. A company is a family of legal entities, joined by parent UEI or, in part, by an AI reading of names.

Source: Federal contract transactions (Federal Procurement Data System) (U.S. Department of the Treasury, USAspending.gov), data current to Oct 7, 2026, loaded Oct 7, 2026 · FY2024–FY2026.

Source: Federal contract transactions (Federal Procurement Data System) (U.S. Department of the Treasury, USAspending.gov), data current to Oct 7, 2026, loaded Oct 7, 2026.